101
Targeting IL1RAP To Eradicate Leukemia Stem Cells (LSC) In Acute Myeloid Leukemia (AML)
City of Hope
Antibody
Oncology
Target Identification or Validation
• IL1RAP is a good target for immune therapy
• Interleukin-1 receptor accessory protein (IL1RAP, IL1R3) is a coreceptor involved in several signaling pathways including interleukin-1 (IL-1), IL-33, IL-36G, and stem cell factor (SCF).
• Signaling by IL-1 requires the formation of a cell surface receptor complex involving IL-1, interleukin-1 receptor type 1 (IL1R1), and IL1RAP. Lack of IL1RAP completely abrogates cellular responses to IL1.
• IL1RAP is present on the cell surface of candidate chronic myeloid leukemia LSCs, AML blasts and CD34+ cells which include LSCs, and myelodysplastic syndrome, but not on normal HSC.
• Studies with IL1RAP-/- knockout mice indicate that IL1RAP is dispensable for normal HSC function.
WO2021030484A2
